A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best, and for Whom
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Thase, MD
- Phone Number: 215-746-6680
- Email: thase@pennmedicine.upenn.edu
Study Contact Backup
- Name: Keith E Bredemeier, PhD
- Phone Number: 215-746-3327
- Email: kbredem@udel.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Birmingham VA Healthcare System
-
-
California
-
Menlo Park, California, United States, 94025
- VA Palo Alto Healthcare System
-
San Diego, California, United States, 92161
- VA San Diego Healthcare System
-
-
Pennsylvania
-
Coatesville, Pennsylvania, United States, 19320
- Coatesville VA Medicial Center
-
Philadelphia, Pennsylvania, United States, 19104
- Corporal Michael J. Crescenz VA Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75216
- VA North Texas Healthcare System
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53295
- Milwaukee VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- DSM-5 diagnosis of Posttraumatic Stress Disorder
- military veteran
- fluent in English
- willing to participate in PE, pharmacotherapy, or both
- capable of providing informed consent
Exclusion Criteria:
- suicidal ideation with intent and/or plan, or suicidal behavior in the past month
- active psychosis
- history of manic episode(s)
- a failed trial of Prolonged Exposure therapy or paroxetine and venlafaxine XR
- ongoing medical conditions or treatments that would contraindicate initiating these treatments (e.g., medications that have potential interactions with paroxetine and venlafaxine such as MAO inhibitors)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Prolonged Exposure Therapy
8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
|
A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
|
|
Active Comparator: Pharmacotherapy
20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
|
Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
Other Names:
|
|
Active Comparator: Combined treatment (Prolonged Exposure and Pharmacotherapy)
8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
|
A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change during active treatment on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Time Frame: baseline to 14 weeks
|
The CAPS-5 is a structured clinical interview that assesses the presence and severity of PTSD symptoms.
Twenty items are rated on a 5-point scale from 0 (absent) to 4 (extremely/incapacitating).
Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity
|
baseline to 14 weeks
|
|
Change during follow-up on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Time Frame: 14 weeks to 40 weeks
|
The CAPS-5 is a structured clinical interview that assesses the presence and severity of PTSD symptoms.
Twenty items are rated on a 5-point scale from 0 (absent) to 4 (extremely/incapacitating).
Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity
|
14 weeks to 40 weeks
|
|
Change during active treatment on the PTSD Checklist for DSM-5 (PCL-5)
Time Frame: baseline to 14 weeks
|
The PCL-5 is a 20-item self-report measure examining the presence and severity of recent PTSD symptoms using a 0 (not at all) to 4 (extremely) point Likert scale.
Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.
|
baseline to 14 weeks
|
|
Change during follow-up on the PTSD Checklist for DSM-5 (PCL-5)
Time Frame: 14 weeks to 40 weeks
|
The PCL-5 is a 20-item self-report measure examining the presence and severity of recent PTSD symptoms using a 0 (not at all) to 4 (extremely) point Likert scale.
Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.
|
14 weeks to 40 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change during active treatment on the Quick Inventory of Depressive Symptoms - clinician rated (QIDS-C)
Time Frame: baseline to 14 weeks
|
The QIDS is a structured interview that assesses presence and severity of depressive disorder symptoms.
Sixteen items are rated on a 0-3 scale and summed.
Total scores range from 0 to 27 (higher scores indicate greater depression symptom severity).
|
baseline to 14 weeks
|
|
Change during follow-up on the Quick Inventory of Depressive Symptoms - clinician rated (QIDS-C)
Time Frame: 14 weeks to 40 weeks
|
The QIDS is a structured interview that assesses presence and severity of depressive disorder symptoms.
Sixteen items are rated on a 0-3 scale and summed.
Total scores range from 0 to 27 (higher scores indicate greater depression symptom severity).
|
14 weeks to 40 weeks
|
|
Change during active treatment on the Patient Health Questionnaire depression module (PHQ-9)
Time Frame: baseline to 14 weeks
|
This self-report inventory consists of 9 items that assess depressive symptoms over the past 2 weeks using a scale from 0 (not at all) to 3 (nearly every).
Total scores range from 0 to 27, with higher scores indicating greater depression symptom severity.
|
baseline to 14 weeks
|
|
Change during follow-up on the Patient Health Questionnaire depression module (PHQ-9)
Time Frame: 14 weeks to 40 weeks
|
This self-report inventory consists of 9 items that assess depressive symptoms over the past 2 weeks using a scale from 0 (not at all) to 3 (nearly every).
Total scores range from 0 to 27, with higher scores indicating greater depression symptom severity.
|
14 weeks to 40 weeks
|
|
Change during active treatment on the Social and Occupational Functioning Assessment Scale (SOFAS)
Time Frame: baseline to 14 weeks
|
The SOFAS is a global clinical rating scale of current functioning, ranging from 0 to 100 (with higher scores indicated better functioning), which focuses on impairments in social and occupational functioning caused by physical and mental health problems (rated independent of symptom severity).
|
baseline to 14 weeks
|
|
Change during follow-up on the Social and Occupational Functioning Assessment Scale (SOFAS)
Time Frame: 14 weeks to 40 weeks
|
The SOFAS is a global clinical rating scale of current functioning, ranging from 0 to 100 (with higher scores indicated better functioning), which focuses on impairments in social and occupational functioning caused by physical and mental health problems (rated independent of symptom severity).
|
14 weeks to 40 weeks
|
|
Change during active treatment on the Veterans RAND 12-item Health Survey (VR-12)
Time Frame: baseline to 14 weeks
|
This brief self-report scale was developed (with modified items from the 36 item Short-Form Health Survey) and validated specifically for veterans to assess health-related quality of life, based on reported functioning in multiple domains (e.g., general health, social activities, role limitations).
Patients receive a physical component score and a mental component score, and both are scaled so that a score of 50 corresponds to the population average (higher scores indicate better quality of life).
|
baseline to 14 weeks
|
|
Change during follow-up on the Veterans RAND 12-item Health Survey (VR-12)
Time Frame: 14 weeks to 40 weeks
|
This brief self-report scale was developed (with modified items from the 36 item Short-Form Health Survey) and validated specifically for veterans to assess health-related quality of life, based on reported functioning in multiple domains (e.g., general health, social activities, role limitations).
Patients receive a physical component score and a mental component score, and both are scaled so that a score of 50 corresponds to the population average (higher scores indicate better quality of life).
|
14 weeks to 40 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Trauma and Stressor Related Disorders
- Mental Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Therapeutics
- Lipids
- Hydrocarbons
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Amines
- Piperidines
- Alcohols
- Phenethylamines
- Ethylamines
- Cyclohexanols
- Hexanols
- Fatty Alcohols
- Venlafaxine Hydrochloride
- Paroxetine
- Drug Therapy
Other Study ID Numbers
Other Study ID Numbers
- 1620949-1
- CER-2020C1-19382 (Other Grant/Funding Number: Patient-Centered Outcomes Research Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.